Aaron,
I wonder if we will see PLE results at all (or if we do, they may be played down).
My sense is PLE is plan B for Clinuvel at this point.
It is all about orhpan indications. Why? See Cerezyme (Gauchers Disease) to understand why. It is based on:
- small number of patients (5,000 in the case of Gauchers)
- extremely high price for the drug (US$200,000 in case of Gauchers / Cerezye)
- high govt subsidies
Clinuvel can make substantial earnings from orphan indications, and can do so very quickly. It is the quickest route to market, and earnings.
PLE is a broad based market strategy. It is incompatible with an orphan approach - gestation period is longer, pricing strategy different (because low govt subsidies for broader application).
My sense is PLE is plan B at this stage. They'll pursue it further down the track once they have they are up and running with their orphan indications.
- Forums
- ASX - By Stock
- CUV
- volume in europe, a precursor?
volume in europe, a precursor?, page-2
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CUV (ASX) to my watchlist
(20min delay)
|
|||||
Last
$14.02 |
Change
0.000(0.00%) |
Mkt cap ! $702.0M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 369 | $14.72 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.32 | 165 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 367 | 14.720 |
2 | 594 | 14.500 |
1 | 36 | 14.200 |
2 | 350 | 14.030 |
1 | 690 | 14.020 |
Price($) | Vol. | No. |
---|---|---|
13.320 | 21 | 1 |
14.000 | 80 | 1 |
14.100 | 40 | 1 |
14.250 | 500 | 1 |
14.300 | 760 | 3 |
Last trade - 09.43am 01/10/2024 (20 minute delay) ? |
Featured News
CUV (ASX) Chart |
Day chart unavailable
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
Previous Video
Next Video
SPONSORED BY The Market Online